(ELF) ELF Beauty - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US26856L1035
Stock: Cosmetics, Skincare, Makeup
Total Rating 42
Risk 72
Buy Signal -0.70
| Risk 5d forecast | |
|---|---|
| Volatility | 68.9% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.53 |
| Alpha | -19.06 |
| Character TTM | |
|---|---|
| Beta | 1.277 |
| Beta Downside | -0.184 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.09% |
| CAGR/Max DD | 0.04 |
EPS (Earnings per Share)
Revenue
Description: ELF ELF Beauty March 05, 2026
e.l.f. Beauty, Inc. (ELF) is a beauty company offering cosmetics and skincare. The company operates globally, selling products under multiple brands including e.l.f. Cosmetics, e.l.f. Skin, Well People, Naturium, and Keys Soulcare. The beauty industry is characterized by strong brand loyalty and frequent product innovation.
ELF utilizes a hybrid sales model, distributing through national and international retailers while also maintaining a direct-to-consumer e-commerce channel. This dual approach allows for broad market penetration and direct customer engagement, a common strategy for consumer goods companies.
Founded in 2004 and headquartered in Oakland, California, the company was formerly known as J.A. Cosmetics Holdings, Inc. For a deeper dive into ELFs financial performance and market position, further research on ValueRay is recommended.
Headlines to watch out for
- New product launches boost e.l.f. Cosmetics brand sales
- Retailer partnerships expand distribution channels globally
- Acquisition strategy drives portfolio growth and market share
- E-commerce growth increases direct-to-consumer revenue
- Input cost fluctuations impact gross profit margins
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 103.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 7.29 > 1.0 |
| NWC/Revenue: 29.43% < 20% (prev 20.37%; Δ 9.06% < -1%) |
| CFO/TA 0.11 > 3% & CFO 246.2m > Net Income 103.9m |
| Net Debt (729.3m) to EBITDA (241.1m): 3.03 < 3 |
| Current Ratio: 2.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.2m) vs 12m ago 3.15% < -2% |
| Gross Margin: 70.27% > 18% (prev 0.71%; Δ 6.96k% > 0.5%) |
| Asset Turnover: 84.70% > 50% (prev 102.9%; Δ -18.24% > 0%) |
| Interest Coverage Ratio: 6.48 > 6 (EBITDA TTM 241.1m / Interest Expense TTM 27.0m) |
Altman Z'' 1.67
| A: 0.19 (Total Current Assets 701.6m - Total Current Liabilities 254.3m) / Total Assets 2.32b |
| B: -0.05 (Retained Earnings -106.6m / Total Assets 2.32b) |
| C: 0.10 (EBIT TTM 174.8m / Avg Total Assets 1.79b) |
| D: -0.09 (Book Value of Equity -104.9m / Total Liabilities 1.16b) |
| Altman-Z'' Score: 1.67 = BB |
Beneish M -2.92
| DSRI: 0.87 (Receivables 190.3m/187.7m, Revenue 1.52b/1.30b) |
| GMI: 1.01 (GM 70.27% / 71.11%) |
| AQI: 1.25 (AQ_t 0.68 / AQ_t-1 0.54) |
| SGI: 1.17 (Revenue 1.52b / 1.30b) |
| TATA: -0.06 (NI 103.9m - CFO 246.2m) / TA 2.32b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of ELF shares?
As of March 14, 2026, the stock is trading at USD 79.95 with a total of 1,467,313 shares traded.
Over the past week, the price has changed by -10.95%, over one month by -9.93%, over three months by -6.60% and over the past year by +16.58%.
Over the past week, the price has changed by -10.95%, over one month by -9.93%, over three months by -6.60% and over the past year by +16.58%.
Is ELF a buy, sell or hold?
ELF Beauty has received a consensus analysts rating of 4.24.
Therefore, it is recommended to buy ELF.
- StrongBuy: 9
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 112.8 | 41.1% |
| Analysts Target Price | 112.8 | 41.1% |
ELF Fundamental Data Overview March 12, 2026
P/E Trailing = 45.4746
P/E Forward = 22.1239
P/S = 3.1584
P/B = 4.091
P/EG = 2.03
Revenue TTM = 1.52b USD
EBIT TTM = 174.8m USD
EBITDA TTM = 241.1m USD
Long Term Debt = 816.7m USD (from longTermDebt, last quarter)
Short Term Debt = 42.0m USD (from shortTermDebt, last quarter)
Debt = 926.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 729.3m USD (from netDebt column, last quarter)
Enterprise Value = 5.53b USD (4.80b + Debt 926.1m - CCE 196.8m)
Interest Coverage Ratio = 6.48 (Ebit TTM 174.8m / Interest Expense TTM 27.0m)
EV/FCF = 25.77x (Enterprise Value 5.53b / FCF TTM 214.5m)
FCF Yield = 3.88% (FCF TTM 214.5m / Enterprise Value 5.53b)
FCF Margin = 14.12% (FCF TTM 214.5m / Revenue TTM 1.52b)
Net Margin = 6.84% (Net Income TTM 103.9m / Revenue TTM 1.52b)
Gross Margin = 70.27% ((Revenue TTM 1.52b - Cost of Revenue TTM 451.9m) / Revenue TTM)
Gross Margin QoQ = 70.99% (prev 69.45%)
Tobins Q-Ratio = 2.38 (Enterprise Value 5.53b / Total Assets 2.32b)
Interest Expense / Debt = 1.33% (Interest Expense 12.4m / Debt 926.1m)
Taxrate = 26.90% (14.5m / 53.9m)
NOPAT = 127.8m (EBIT 174.8m * (1 - 26.90%))
Current Ratio = 2.76 (Total Current Assets 701.6m / Total Current Liabilities 254.3m)
Debt / Equity = 0.80 (Debt 926.1m / totalStockholderEquity, last quarter 1.16b)
Debt / EBITDA = 3.03 (Net Debt 729.3m / EBITDA 241.1m)
Debt / FCF = 3.40 (Net Debt 729.3m / FCF TTM 214.5m)
Total Stockholder Equity = 966.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.79% (Net Income 103.9m / Total Assets 2.32b)
RoE = 10.75% (Net Income TTM 103.9m / Total Stockholder Equity 966.6m)
RoCE = 9.80% (EBIT 174.8m / Capital Employed (Equity 966.6m + L.T.Debt 816.7m))
RoIC = 8.41% (NOPAT 127.8m / Invested Capital 1.52b)
WACC = 9.06% (E(4.80b)/V(5.73b) * Re(10.62%) + D(926.1m)/V(5.73b) * Rd(1.33%) * (1-Tc(0.27)))
Discount Rate = 10.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.84%
[DCF] Terminal Value 77.89% ; FCFF base≈138.6m ; Y1≈170.9m ; Y5≈291.1m
[DCF] Fair Price = 56.17 (EV 4.05b - Net Debt 729.3m = Equity 3.32b / Shares 59.1m; r=9.06% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 72.61 | EPS CAGR: 82.47% | SUE: 4.0 | # QB: 1
Revenue Correlation: 95.03 | Revenue CAGR: 50.71% | SUE: 1.56 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.02 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=13
EPS next Year (2027-03-31): EPS=3.65 | Chg7d=+0.000 | Chg30d=-0.001 | Revisions Net=+10 | Growth EPS=+17.8% | Growth Revenue=+17.1%
[Analyst] Revisions Ratio: -0.14 (3 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.4% (Discount Rate 10.6% - Earnings Yield 2.2%)
[Growth] Growth Spread = +21.6% (Analyst 30.0% - Implied 8.4%)
P/E Forward = 22.1239
P/S = 3.1584
P/B = 4.091
P/EG = 2.03
Revenue TTM = 1.52b USD
EBIT TTM = 174.8m USD
EBITDA TTM = 241.1m USD
Long Term Debt = 816.7m USD (from longTermDebt, last quarter)
Short Term Debt = 42.0m USD (from shortTermDebt, last quarter)
Debt = 926.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 729.3m USD (from netDebt column, last quarter)
Enterprise Value = 5.53b USD (4.80b + Debt 926.1m - CCE 196.8m)
Interest Coverage Ratio = 6.48 (Ebit TTM 174.8m / Interest Expense TTM 27.0m)
EV/FCF = 25.77x (Enterprise Value 5.53b / FCF TTM 214.5m)
FCF Yield = 3.88% (FCF TTM 214.5m / Enterprise Value 5.53b)
FCF Margin = 14.12% (FCF TTM 214.5m / Revenue TTM 1.52b)
Net Margin = 6.84% (Net Income TTM 103.9m / Revenue TTM 1.52b)
Gross Margin = 70.27% ((Revenue TTM 1.52b - Cost of Revenue TTM 451.9m) / Revenue TTM)
Gross Margin QoQ = 70.99% (prev 69.45%)
Tobins Q-Ratio = 2.38 (Enterprise Value 5.53b / Total Assets 2.32b)
Interest Expense / Debt = 1.33% (Interest Expense 12.4m / Debt 926.1m)
Taxrate = 26.90% (14.5m / 53.9m)
NOPAT = 127.8m (EBIT 174.8m * (1 - 26.90%))
Current Ratio = 2.76 (Total Current Assets 701.6m / Total Current Liabilities 254.3m)
Debt / Equity = 0.80 (Debt 926.1m / totalStockholderEquity, last quarter 1.16b)
Debt / EBITDA = 3.03 (Net Debt 729.3m / EBITDA 241.1m)
Debt / FCF = 3.40 (Net Debt 729.3m / FCF TTM 214.5m)
Total Stockholder Equity = 966.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.79% (Net Income 103.9m / Total Assets 2.32b)
RoE = 10.75% (Net Income TTM 103.9m / Total Stockholder Equity 966.6m)
RoCE = 9.80% (EBIT 174.8m / Capital Employed (Equity 966.6m + L.T.Debt 816.7m))
RoIC = 8.41% (NOPAT 127.8m / Invested Capital 1.52b)
WACC = 9.06% (E(4.80b)/V(5.73b) * Re(10.62%) + D(926.1m)/V(5.73b) * Rd(1.33%) * (1-Tc(0.27)))
Discount Rate = 10.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.84%
[DCF] Terminal Value 77.89% ; FCFF base≈138.6m ; Y1≈170.9m ; Y5≈291.1m
[DCF] Fair Price = 56.17 (EV 4.05b - Net Debt 729.3m = Equity 3.32b / Shares 59.1m; r=9.06% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 72.61 | EPS CAGR: 82.47% | SUE: 4.0 | # QB: 1
Revenue Correlation: 95.03 | Revenue CAGR: 50.71% | SUE: 1.56 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.02 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=13
EPS next Year (2027-03-31): EPS=3.65 | Chg7d=+0.000 | Chg30d=-0.001 | Revisions Net=+10 | Growth EPS=+17.8% | Growth Revenue=+17.1%
[Analyst] Revisions Ratio: -0.14 (3 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.4% (Discount Rate 10.6% - Earnings Yield 2.2%)
[Growth] Growth Spread = +21.6% (Analyst 30.0% - Implied 8.4%)